Revatis S.A. • Enrolment of the first patient in the clinical trial investigating the use of Revatis stem cells in the treatment of immune-mediated keratitis in horses

A significant milestone for Revatis: the company has enrolled its first clinical case using allogeneic muscle-derived stem cells, selected via a compatibility test developed in collaboration with Progenus and supported by published preclinical data.

This first application concerns immune-mediated keratitis in horses, drawing directly on recently published findings.

Subconjunctival autologous muscle‐derived mesenchymal stem cell therapy: A novel, minimally invasive approach for treating equine immune‐mediated keratitis - Narinx - 2024 - Veterinary Ophthalmology - Wiley Online Library

#ophtalmology #stemcells #horse #regenerativemedicine #cellandgenetherapy #immk